Biomedical Engineering Reference
In-Depth Information
68. Tabernero, J.,
Dose- and schedule-dependent inhibition of the
mammalian target of rapamycin pathway with everolimus: a phase
I tumor pharmacodynamic study in patients with advanced solid
tumors.
et al.
J Clin Oncol
26
, 1603-1610 (2008).
69. Fong, P.C.,
Inhibition of poly(ADP-ribose) polymerase in tumors
from BRCA mutation carriers.
et al.
N Engl J Med
361
, 123-134 (2009).
70. Fong, P.C.,
Poly(ADP)-ribose polymerase inhibition: frequent
durable responses in BRCA carrier ovarian cancer correlating with
platinum-free interval.
et al.
, 2512-2519 (2010).
71. Ashworth, A.A synthetic lethal therapeutic approach: poly(ADP) ribose
polymerase inhibitors for the treatment of cancers deficient in DNA
double-strand break repair.
J Clin Oncol
28
J Clin Oncol
26
, 3785-3790 (2008).
72. Gelmon, K.A.,
Olaparib in patients with recurrent high-grade
serous or poorly differentiated ovarian carcinoma or triple-negative
breast cancer: a phase 2, multicentre, open-label, non-randomised
study.
et al.
, 852-861 (2011).
73. Yang, S.X. Bevacizumab and breast cancer: current therapeutic progress
and future perspectives.
Lancet Oncol
12
Expert Rev Anticancer Ther
9
, 1715-1725
(2009).
74. Soria, J.C.,
et al.
Added value of molecular targeted agents in oncology.
Ann Oncol
22
, 1703-1716 (2011).
75. Marty, M.,
Randomized phase II trial of the efficacy and safety
of trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast cancer
administered as first-line treatment: the M77001 study group.
et al.
J Clin
, 4265-4274 (2005).
76. Romond, E.H.,
Oncol
23
Trastuzumab plus adjuvant chemotherapy for
operable HER2-positive breast cancer.
et al.
N Engl J Med
353
, 1673-1684
(2005).
77. Piccart-Gebhart, M.J.,
Trastuzumab after adjuvant chemotherapy
in HER2-positive breast cancer.
et al.
N Engl J Med
353
, 1659-1672 (2005).
78. Smith, I.,
2-year follow-up of trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer: a randomised controlled
trial.
et al.
, 29-36 (2007).
79. De Laurentiis, M.,
Lancet
369
Taxane-based combinations as adjuvant
chemotherapy of early breast cancer: a meta-analysis of randomized
trials.
et al.
J Clin Oncol
26
, 44-53 (2008).
